With the tremendous leap of various adjuvant therapies including endocrine therapy, targeted therapy, immune checkpoint inhibitors (anti-programmed cell death protein-1 therapy, anti-PD1 therapy), platinum-based chemotherapeutic agents, the risk of BC-related deaths of patients has been greatly reduced. The gene discussed is PDCD1; the disease is breast cancer.